In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kratom Group Contests FDA's Opioid Finding, Requests Joint Meeting With NIDA

This article is powered by The Rose Sheet

Executive Summary

American Kratom Association accuses FDA of using “inaccurate, extrapolated and distorted” information on adverse events and deaths allegedly associated with the use of kratom to justify scheduling it as a controlled substance. After FDA Commissioner Gottlieb says the criticism is unfounded and kratom has no future as a dietary ingredient in the US, the group asks for joint meeting with NIDA to discuss "public health policy that allows for consumers to safely use natural kratom."

Advertisement

Related Content

Kratom Industry GMPs Target Swaying FDA By Exceeding Agency Standards
Clinical Trials For Supplement Claims Not An FTC Rule, But A Standard
Kratom Group Sharpens Criticism Of 'Opioid' Finding In FDA's Report To DEA
Failed NDIs, FDA's Opioid Concerns Don't Stop Kratom Supplement Sales
Salmonella In Kratom, Like Use Of The Herb, Exceeds FDA Expectations
It's Complicated: FDA Prohibits CBD In Supplements, Enforcement Priority On Disease Claims
Recalls: FDA Reports Salmonella Contamination In More Kratom Supplements
AHPA Backs NDI Filing For Kratom, Experts Question FDA Enforcement
FDA's Opioid Label For Kratom Called Misbranding By Marketers
DEA Proposal To Schedule Kratom Stirs Wave Of Opposition

Topics

Advertisement
UsernamePublicRestriction

Register

RS121784

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel